Business Context and Reporting Period
Anika Therapeutics, Inc. (ANIK) filed its Form 10-Q for the quarterly period ended March 31, 2026. The company is a global leader in hyaluronic acid (HA) innovations, focusing on osteoarthritis (OA) pain management and orthopedic regenerative solutions. Following strategic divestitures of Arthrosurface (October 2024) and Parcus Medical (March 2025), the company has shifted its focus entirely to its core OA and regenerative businesses. As of April 21, 2026, there were 13,305,624 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $29.6 million | $26.2 million |
| Gross Profit | $19.0 million | $14.7 million |
| Gross Margin | 64% | 56% |
| Net Loss | $(5.1) million | $(4.9) million |
| Loss Per Share (Diluted) | $(0.37) | $(0.34) |
| Cash and Cash Equivalents | $41.0 million | $53.4 million |
| Working Capital | $72.6 million | $80.2 million |
| Operating Cash Flow | $(4.8) million | $(0.1) million |
Debt and Liquidity: The company has no outstanding borrowings under its $75.0 million revolving credit facility. Total liabilities were $45.5 million, primarily consisting of lease liabilities ($23.8 million) and current accrued expenses ($14.6 million).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 13% year-over-year, driven by a 14% increase in the OEM channel (primarily J&J MedTech) and a 12% increase in the Commercial channel. International OA pain management and regenerative product sales contributed to the growth.
- Margin Expansion: Gross margin improved from 56% to 64% due to higher sales volume, increased production efficiency, and lower inventory reserves.
- Expense Increases: Operating expenses rose 29% to $24.5 million. Selling, General, and Administrative (SG&A) expenses increased 38% ($4.9 million), primarily due to a $3.3 million increase in stock-based compensation (accelerated due to CEO transition) and $1.6 million in restructuring severance costs.
- Cash Flow: Operating cash flow turned negative ($4.8 million used) compared to a near-neutral position in the prior year, driven by inventory build-up for safety stock and higher accounts receivable.
Guidance, Outlook, and Risks
- Strategic Focus: Management is focused on advancing the Cingal product for U.S. FDA approval and expanding the Integrity Implant System and Hyalofast regenerative portfolio. A PMA for Hyalofast was submitted to the FDA in October 2025, targeting a 2027 U.S. launch.
- Restructuring: The company initiated a workforce reduction to reduce G&A expenses, with total expected costs of approximately $2.3 million. Actions are expected to be substantially completed by the end of Q2 2026.
- Share Repurchases: The company completed its $15.0 million Rule 10b5-1 plan with Clear Street LLC in April 2026 and is no longer actively repurchasing stock. As of March 31, 2026, 73% of the $40.0 million 2024 Share Repurchase Program had been utilized.
- Risks: Key risks include the timing of FDA approvals for Cingal and Hyalofast, dependence on key customers (J&J MedTech represented 47% of revenue), and the ability to manage cash burn while investing in R&D.
Investor Verification Checklist
- CEO Transition Impact: Verify the long-term impact of the January 2026 CEO transition and the associated $3.3 million accelerated stock-based compensation expense on future profitability.
- Regulatory Milestones: Monitor progress on the Cingal NDA submission and the Hyalofast PMA review, as these are critical for future revenue growth.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate ($4.8 million operating cash outflow in Q1) against the $41.0 million cash balance and the $75.0 million credit facility.
- Customer Concentration: Review the stability of the relationship with J&J MedTech, which accounts for nearly half of total revenue.
- Restructuring Completion: Confirm the timeline and cost savings realization from the ongoing workforce reduction plan.